[PRESS RELEASE] – EDMONTON, Alberta, Sept. 18, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced a five-year investment into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany. Building on best practices proven at Aurora's Canadian facilities, these improvements will increase flower growth capacity, product quality and drive cost efficiency.
"This investment marks a significant milestone in our commitment to operational excellence and long-term growth in Europe," said Alex Miller, executive vice president of operations, science and supply chain at Aurora. "These upgrades will strengthen our supply chain resilience, expand our domestic capabilities in EU-GMP certified manufacturing, and position us to best meet the growing demand for high-quality medical cannabis in Europe with precision and efficiency."
Aurora's global manufacturing network upholds the highest manufacturing standards that will be adopted at the German facility. With the goal of maximizing cultivation volume, the upgrades include commissioning additional grow rooms, new irrigation and lighting systems in existing rooms, and transitioning to hang dry and dry trim.
As one of only three licensed cultivation facilities in the country, Aurora Leuna plays a pivotal role in supplying high-quality, locally grown medical cannabis to meet the needs of Germany's expanding patient base. Aurora Leuna currently grows cultivars under the IndiMed brand, and this expansion will enable the site to grow additional cultivars available from Aurora's leading genetics library. By continuously investing in operational capabilities, Aurora is best positioned to serve international markets at the highest standards.
